After watching the American Regent video:

https://www.americanregent.com/video/

And after reviewing their distributor list, which includes the usual big names: McKesson, AmerisourceBergen, and Cardinal Health:

https://americanregent.com/distributors/

I've been wondering exactly what services American Regent will be providing.

From the video, it seems like they will be performing similar aseptic fill finish services like Ajinomoto Bio-Pharma, who CytoDyn already has an agreement with:

https://www.prnewswire.com/news-releases/ajin...51247.html

With American Regent owned by Daiichi Sankyo a Tokyo-based company, and Ajinomoto Bio-Pharma owned by Ajinomoto Kabushiki-gaisha another Tokyo-based company -- I think we can all agree that the notion that CytoDyn is using an American company is an empty argument.

I understand that aseptic fill finish and distribution are two different functions of the supply chain. It just surprises me that CytoDyn would issue a PR that identifies American Regent as their "distributor" for COVID, as I would think they would still need distributors/wholesalers like the ones listed on the American Regent website.

It's hard for me to imagine that American Regent will act as the 'middle man' between CytoDyn and distributors like McKesson, AmerisourceBergen, and Cardinal Health -- or that an arrangement like that would be cost effective for CytoDyn.